Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience.

Berinstein JA, Karl T, Patel A, Dolinger M, Barrett TA, Ahmed W, Click B, Steiner CA, Dulaney D, Levine J, Hassan SA, Perry C, Flomenhoft D, Ungaro RC, Berinstein EM, Sheehan J, Cohen-Mekelburg S, Regal RE, Stidham RW, Bishu S, Colombel JF, Higgins PDR. Effectiveness of Upadacitinib for Patients with Acute Severe Ulcerative Colitis: A Multi-Center Experience. The American journal of gastroenterology. 2024 Jan 26.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


Abstract:

BACKGROUND: A significant proportion of patients with acute severe ulcerative colitis (ASUC) require colectomy. METHODS: ASUC patients treated with upadacitinib and IV corticosteroids at five hospitals are presented. The primary outcome was 90-day colectomy rate. Secondary outcomes included frequency of steroid-free clinical remission, adverse events, and all-cause readmissions. RESULTS: Of the 25 ASUC patients treated with upadacitinib, 6 (24%) patients underwent colectomy, 15 (83%) patients experienced steroid-free clinical remission, one (4%) patient experiencd a venous thromboembolic event, one (4%) patient experienced COVID-19, while five (20%) patients were readmitted. CONCLUSION: Upadacitinib along with IV corticosteroids may be an effective treatment for ASUC.




Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.